JP2023525778A5 - - Google Patents

Info

Publication number
JP2023525778A5
JP2023525778A5 JP2022568460A JP2022568460A JP2023525778A5 JP 2023525778 A5 JP2023525778 A5 JP 2023525778A5 JP 2022568460 A JP2022568460 A JP 2022568460A JP 2022568460 A JP2022568460 A JP 2022568460A JP 2023525778 A5 JP2023525778 A5 JP 2023525778A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequences
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022568460A
Other languages
English (en)
Japanese (ja)
Other versions
JP7883955B2 (ja
JP2023525778A (ja
Filing date
Publication date
Priority claimed from CN202010394296.5A external-priority patent/CN113637073B/zh
Application filed filed Critical
Publication of JP2023525778A publication Critical patent/JP2023525778A/ja
Publication of JP2023525778A5 publication Critical patent/JP2023525778A5/ja
Application granted granted Critical
Publication of JP7883955B2 publication Critical patent/JP7883955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022568460A 2020-05-11 2021-05-07 抗bcma抗体およびキメラ抗原受容体 Active JP7883955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020103942965 2020-05-11
CN202010394296.5A CN113637073B (zh) 2020-05-11 2020-05-11 Bcma抗体及其制备和应用
PCT/US2021/031299 WO2021231213A1 (en) 2020-05-11 2021-05-07 Anti-bcma antibodies and chimeric antigen receptors

Publications (3)

Publication Number Publication Date
JP2023525778A JP2023525778A (ja) 2023-06-19
JP2023525778A5 true JP2023525778A5 (cg-RX-API-DMAC7.html) 2024-02-21
JP7883955B2 JP7883955B2 (ja) 2026-07-02

Family

ID=78415523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568460A Active JP7883955B2 (ja) 2020-05-11 2021-05-07 抗bcma抗体およびキメラ抗原受容体

Country Status (5)

Country Link
US (1) US12673071B2 (cg-RX-API-DMAC7.html)
EP (1) EP4149967A4 (cg-RX-API-DMAC7.html)
JP (1) JP7883955B2 (cg-RX-API-DMAC7.html)
CN (1) CN113637073B (cg-RX-API-DMAC7.html)
WO (1) WO2021231213A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333134A (zh) * 2021-12-22 2023-06-27 上海君实生物医药科技股份有限公司 抗bcma抗体及其用途
CN117003871A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN116063521B (zh) * 2022-10-31 2024-05-14 北京奇迈永华生物科技有限公司 靶向bcma的抗体及其所构成的嵌合抗原受体
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
CN119119274B (zh) * 2024-09-26 2026-08-11 北京昌盛鸿途生物科技有限公司 一种靶向bcma的cart细胞及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
US8840890B2 (en) * 2008-11-12 2014-09-23 University Of Maryland, Baltimore Rapid expression cloning of human monoclonal antibodies from memory B cells
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
JP6815329B2 (ja) * 2015-03-23 2021-01-20 バイエル ファーマ アクチエンゲゼルシャフト 抗ceacam6抗体およびその使用
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
CN105777911B (zh) * 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
UA126813C2 (uk) 2017-08-01 2023-02-08 Медімм'Юн, Ллк Моноклональний кон’югат антитіло-лікарський засіб до bcma
CN116836297A (zh) 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用

Similar Documents

Publication Publication Date Title
IL317912A (en) A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
US11649286B2 (en) Tri-specific antibodies
Labrijn et al. Bispecific antibodies: a mechanistic review of the pipeline
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
JP2023553390A5 (cg-RX-API-DMAC7.html)
JP2021087455A5 (cg-RX-API-DMAC7.html)
JP2021526844A5 (cg-RX-API-DMAC7.html)
US11787863B2 (en) Multi-specific antibodies and methods of making and using thereof
JP2020010699A5 (cg-RX-API-DMAC7.html)
JP7853916B2 (ja) 免疫複合体
JP2018525382A5 (cg-RX-API-DMAC7.html)
JP2022551757A5 (cg-RX-API-DMAC7.html)
JP2017522879A5 (cg-RX-API-DMAC7.html)
AU2022380722A1 (en) Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
JP2024537772A5 (cg-RX-API-DMAC7.html)
IL311600A (en) Antibodies targeting BAFF-R and their use
JP2023524997A5 (cg-RX-API-DMAC7.html)
JP2024539506A5 (cg-RX-API-DMAC7.html)
JP7503215B2 (ja) Cd30及びcd3に結合する抗体
US20250043001A1 (en) Anti-cd28 compositions
JP2024504162A5 (cg-RX-API-DMAC7.html)
JP2022508529A (ja) 二重標的抗原結合分子
JP2023554467A5 (cg-RX-API-DMAC7.html)
JP2021524451A (ja) 最適化済みgp41結合分子及びその使用